ByTrending Posts
Takeda Announces Positive Phase III Results for AI-Discovered…
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Geneva inaugurates first artificial intelligence health hub at…
GENEVA, Dec. 8, 2025 — Geneva has officially inaugurated its first artificial intelligence health hub at Campus Biotech,…
Cradle AI-powered protein engineering platform serving six of…
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration…
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Is Merck and Nvidia’s KERMT Model the Breakthrough…
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI model trained on…
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance…
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine…
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will…
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI…
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
Trending Posts
Latest Stories
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device Innovation?
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast)…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics,…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi,…
Gallery
